Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM103 in Advanced Solid Tumors
NCT05971589Phase 1Not yet recruiting
- Sponsor
- Suzhou BlueHorse Therapeutics
- Start
- Aug 2023
- Primary completion
- Apr 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Phase 1, open-label, single-arm trial of LM103 in solid tumor, sponsored by Suzhou BlueHorse Therapeutics. Primary endpoint: Adverse events, Serious adverse event and immune related adverse events at 1 year. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
LM103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05971589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971589.